文献速递肾移植慢性肾脏病

常染色体显性多囊肾病肾移植受者的心血管结局

Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD.
PubMed 文献 · Kidney Int Rep · 2022-06-11

该研究比较了常染色体显性多囊肾病(ADPKD)、糖尿病肾病(DN)及非糖尿病非ADPKD(NDNA)肾移植受者移植前超声心动图异常与移植后主要不良心血管事件(MACE)。ADPKD组移植前左心室肥厚及瓣膜反流率更低,移植后生存及无MACE生存最优,但瓣膜功能恶化且Valsalva窦直径增加。

要点

  • ADPKD肾移植受者移植前左心室肥厚率39.4%,低于DN组的66.4%和NDNA组的48.6%。
  • ADPKD组移植后中位生存18.7年,优于DN组的12.0年和NDNA组的13.8年(P < 0.01)。
  • ADPKD组无MACE生存风险比为0.51(P < 0.001),但移植后瓣膜功能恶化且Valsalva窦直径增加(38.2 vs 39.9 mm,P < 0.01)。

核心结论

  • ADPKD肾移植受者移植前心脏情况最优,患者生存及无MACE生存率更优,但移植后瓣膜功能恶化且Valsalva窦直径增加。

研究设计与样本

  • 回顾性研究,检索1993-2020年肾移植前2年内超声心动图数据及移植后MACE,按性别(男性59.4%)和移植时年龄(57.2 ± 8.8岁)匹配,ADPKD、DN及NDNA组各271例。

主要发现

  • ADPKD组移植时左心室肥厚率39.4%,DN组66.4%,NDNA组48.6%。
  • ADPKD组二尖瓣反流率2.7%,DN组6.3%,NDNA组7.45%;三尖瓣反流率1.8%、6.6%、7.2%。
  • ADPKD组移植时舒张功能障碍25.3%,收缩功能障碍5.6%。
  • ADPKD组移植后中位生存18.7年,DN组12.0年,NDNA组13.8年(P < 0.01)。
  • ADPKD组无MACE生存风险比=0.51(P < 0.001);移植后Valsalva窦直径38.2 vs 39.9 mm(P < 0.01)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cardiovascular disease leads to high morbidity and mortality in patients with kidney failure. Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a systemic disease with various cardiac abnormalities. Details on the cardiovascular profile of patients with ADPKD who are undergoing kidney transplantation (KT) and its progression are limited. METHODS: Echocardiographic data within 2 years before KT (1993-2020), and major adverse cardiovascular events (MACEs) after transplantation were retrieved. The primary outcome is to assess cardiovascular abnormalities on echocardiography at the time of transplantation in ADPKD as compared with patients without ADPKD matched by sex (male, 59.4%) and age at transplantation (57.2 ± 8.8 years). RESULTS: Compared with diabetic nephropathy (DN, n = 271) and nondiabetic, patients without ADPKD (NDNA) (n = 271) at the time of KT, patients with ADPKD (n = 271) had lower rates of left ventricular hypertrophy (LVH) (39.4% vs. 66.4% vs. 48.6%), mitral (2.7% vs. 6.3% vs. 7.45) and tricuspid regurgitations (1.8% vs. 6.6% vs. 7.2%). Patients with ADPKD had less diastolic (25.3%) and systolic (5.6%) dysfunction at time of transplantation. Patients with ADPKD had the most favorable post-transplantation survival (median 18.7 years vs. 12.0 for diabetic nephropathy [DN] and 13.8 years for nondiabetic non-ADPKD [NDNA]; P < 0.01) and the most favorable MACE-free survival rate (hazard ratio = 0.51, P < 0.001). Patients with ADPKD had worsening of their valvular function and an increase in the sinus of Valsalva diameter post-transplantation (38.2 vs. 39.9 mm, P < 0.01). CONCLUSION: ADPKD transplant recipients have the most favorable cardiac profile pretransplantation with better patient survival and MACE-free survival rates but worsening valvular function and increasing sinus of Valsalva diameter, as compared with patients with other kidney diseases.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Chedid M, Kaidbay HD, Wigerinck S, et al. Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD. Kidney Int Rep. 2022. PMID: 36090485. doi:10.1016/j.ekir.2022.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。